Expression of c-met is a strong independent prognostic factor in breast carcinoma

Cancer

Volumn 82, Issue 8, 1998, Pages 1513-1520

  Ghoussoub, Rola A D ^a   Dillon, Deborah A ^a   D'Aquila, Thomas ^a   Rimm, Eric B ^b   Fearon, Eric R ^c   Rimm, David L ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Adhesion; Hepatocyte growth factor receptor; Scatter factor; Survival

Indexed keywords

GROWTH FACTOR RECEPTOR; POLYCLONAL ANTIBODY; SCATTER FACTOR;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; PRIORITY JOURNAL; PROGNOSIS; PROTO ONCOGENE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTORS, ESTROGEN; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0032523074     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1513::AID-CNCR13>3.0.CO;2-7     Document Type: Article

References (45)

1. Bast R, Bates S, Bredt A, Desch C, Fritsche H, Fues L, et al. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. J Clin Oncol 1996;14:2843-77.
2. Weidner N. Prognostic factors in breast carcinoma. Curr Opin Obstet Gynecol 1995;7:4-9.
3. Komada M, Kitamura N. The cell dissociation and motility triggered by scatter factor/hepatocyte growth factor are mediated through the cytoplasmic domain of the c-Met receptor. Oncogene 1993;8:2381-90.
4. Rosen EM, Nigam SK, Goldberg ID. Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction. J Cell Biol 1994;127:1783-7.
5. Niranjan B, Buluwela L, Yant J, Perusinghe N, Atherton A, Phippard D, et al. HGF/SF: a potent cytokine for mammary growth, morphogenesis and development. Development 1995;121:2897-908.
6. Derman MP, Chen JY, Spokes KC, Songyang Z, Cantley LG. An 11-amino acid sequence from c-met initiates epithelial chemotaxis via phosphatidylinositol 3-kinase and phospholipase C. J Biol Chem 1996;271:4251-5.
7. Comoglio PM. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells. EXS 1993;65:131-65.
8. Matsumoto K, Nakamura T. Emerging multipotent aspects of hepatocyte growth factor. J Biochem (Tokyo) 1996; 119:591-600.
9. Bottaro DP, Rubin JS, Faletto DL, Chan AM, Kmiecik TE, Vande WG, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science 1991;251:802-4.
10. Di Renzo M, Narsimhan RP, Olivero M, Bretti S, Giordano S, Medico E, et al. Expression of the Met/HGF receptor in normal and neoplastic human tissues. Oncogene 1991; 6:1997-2003.
11. Prat M, Narsimhan RP, Crepaldi T, Nicotra MR, Natali PG, Comoglio PM. The receptor encoded by the human c-MET oncogene is expressed in hepatocytes, epithelial cells and solid tumors. Int J Cancer 1991;49:323-8.
12. Brinkmann V, Foroutan H, Sachs M, Weidner KM, Birchmeier W. Hepatocyte growth factor/scatter factor induces a variety of tissue-specific morphogenic programs in epithelial cells. J Cell Biol 1995;131:1573-86.
13. Giordano S, Di RM, Narsimhan RP, Cooper CS, Rosa C, Comoglio PM. Biosynthesis of the protein encoded by the c-met proto-oncogene. Oncogene 1989;4:1383-8.
14. Sachs M, Weidner KM, Brinkmann V, Walther I, Obermeier A, Ullrich A, et al. Motogenic and morphogenic activity of epithelial receptor tyrosine kinases. J Cell Biol 1996;133:1095-107.
15. Yamashita J, Ogawa M, Beppu T. Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res Commun Chem Pathol Pharmacol 1993;82:249-52.
16. Wang Y, Selden AC, Morgan N, Stamp GW, Hodgson HJ. Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am J Pathol 1994;144:675-82.
17. Yao Y, Jin L, Fuchs A, Joseph A, Hastings HM, Goldberg ID, et al. Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am J Pathol 1996;149:1707-17.
18. Yamashita J, Ogawa M, Yamashita S, Nomura K, Kuramoto M, Saishoji T, et al. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res 1994;54:1630-3.
19. Tsarfaty I, Resau JH, Rulong S, Keydar I, Faletto DL, Vande WG. The met proto-oncogene receptor and lumen formation. Science 1992;257:1258-61.
20. Nagy J, Clark JS, Cooke A, Campbell AM, Connor JM, Purushotham AD, et al. Expression and loss of heterozygosity of c-met proto-oncogene in primary breast cancer. J Surg Oncol 1995;60:95-9.
21. Nagy J, Curry GW, Hillan KJ, Mckay IC, Mallon E, Purushotham AD, et al. Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surgical Oncol 1996;5:15-21.
22. Jin L, Fuchs A, Schnitt SJ, Yao Y, Joseph A, Lamszus K, et al. Expression of scatter factor and C-met receptor in benign and malignant breast tissue. Cancer 1997;79:749-60.
23. Tuck AB, Park M, Sterns EE, Boag A, Elliott BE. Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. Am J Pathol 1996;148:225-32.
24. Yonemura Y, Kaji M, Hirono Y, Fushida S, Tsugawa K, Fujimura T, et al. Correlation between overexpression of c-met gene and the progression of gastric cancer. Int J Oncol 1996;8:555-60.
25. Humphrey PA, Zhu X, Zarnegar R, Swanson PE, Ratlifl TL, Vollmer RT, et al. Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol 1995;147:386-96.
26. Donegan W. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997;47:28-51.
27. Fisher ER, Redmond C, Fisher B. Histologic grading of breast cancer. Pathol Annu 1980;15:239-51.
28. Norton A, Jordan S, Yeomans P. Brief high-temperature heat denaturation (pressure cooking): a simple and effective method of antigen retrieval for routinely processed specimens. J Pathol 1994;173:371-9.
29. Moghul A, Lin L, Beedle A, Kanbour SA, DeFrances MC, Liu Y, et al. Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. Oncogene 1994;9:2045-52.
30. Byers S, Park M, Sommers C, Seslar S. Breast carcinoma: a collective disorder. Breast Cancer Res Treat 1994;31:203-15.
31. Alanko A, Heinonen E, Scheinin T, Tolppanen EM, Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer 1985;56:1696-700.
32. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983;43:2985-90.
33. Tetu B, Brisson J. Prognostic significance of HER-2/neu oncoprotein expression in node-positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy. Cancer 1994;73:2359-65.
34. Hartmann LC, Ingle JN, Wold LE, Farr GJ, Grill JP, Su JQ, et al. Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer 1994;74:2956-63.
35. Sainsbury JR, Farndon JR, Sherbet GV, Harris AL. Epidermal-growth-factor receptors and oestrogen receptors in human breast cancer. Lancet 1985;1:364-6.
36. Thor AD, Moore DI, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
37. Rimm DL, Sinard JH, Morrow JS. Reduced alpha-catenin and E-cadherin expression in breast cancer. Lab Invest 1995;72:506-12.
38. Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res 1993;53:1696-701.
39. Moll R, Mitze M, Frixen UH, Birchmeier W. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. Am J Pathol 1993;143:1731-42.
40. Weidner KM, Hartmann G, Sachs M, Birchmeier W. Properties and functions of scatter factor/hepatocyte growth factor and its receptor c-Met. Am J Respir Cell Mol Biol 1993;8:229-37.
41. Pepper MS, Matsumoto K, Nakamura T, Orci L, Montesano R. Hepatocyte growth factor increases urokinase-type plasminogen activator (u-PA) and u-PA receptor expression in Madin-Darby canine kidney epithelial cells. J Biol Chem 1992;267:20493-6.
42. Porter JK, Lippman ME. Overview of the biologic markers of breast cancer. Hematol Oncol Clin North Am 1994;8:73-100.
43. Mansour EG, Ravdin PM, Dressler L. Prognostic factors in early breast carcinoma. Cancer 1994;74:381-400.
44. Goldhirsch A, Wood WC, Senn HJ, Click JH, Gelber RD. Meeting highlights: international consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1995;87:1441-5.
45. Bieche I, Champeme MH, Matifas F, Hacene K, Callahan R, Lidereau R. Loss of heterozygosity on chromosome 7q and aggressive primary breast cancer. Lancet 1992;339:139-43.